← Eichor
Condition: Malt Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Malt Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Phase 2 · 2 location(s) · University of Utah · NCT06390956Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
Phase N/A · 7 location(s) · International Extranodal Lymphoma Study Group (IELSG) · NCT06712459Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06504940This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06503276Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 · 4 location(s) · Newave Pharmaceutical Inc · NCT04775745Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Marcela V. Maus, M.D.,Ph.D. · NCT06026319Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
Phase 2 · 2 location(s) · Zhejiang Cancer Hospital · NCT07554898A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · New York Medical College · NCT04491370Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06350318SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06563505Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06806488MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Phase 3 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT04834024Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal
Phase N/A · 50 location(s) · International Extranodal Lymphoma Study Group (IELSG) · NCT05700149Cohort Study for Gastric MALT Lymphoma
Phase N/A · 3 location(s) · Seoul National University Hospital · NCT06454149Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · John Lister · NCT05281809A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Phase 1/Phase 2 · 127 location(s) · BeOne Medicines · NCT05006716Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT07233720Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Phase 4 · 3 location(s) · Beijing Tongren Hospital · NCT07355699MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Phase 1/Phase 2 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT04110301A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Phase 3 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07029217Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients Wit
Phase 3 · 19 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT06082102
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.